Pharma innovation

shutterstock_350093090 [Shutterstock]

Hit hard by austerity, the health systems of EU member states are under huge pressure. Combined with an aging population and the alarming burden of chronic illnesses, EU member states have targeted specific aspects of the incentives granted to the pharma industry in order to decrease drug prices.

In June 2016 particularly, EU health ministers called on the European Commission to perform an overview of the current EU legislative tools and incentives that aim to facilitate investment in the development of medicinal products.

On the other hand, many suggest that such an approach would have detrimental consequences for innovation in the pharma sector. Experts claim that policymakers should instead focus on other healthcare fields to save costs, considering that pharmaceutical expenditure has remained stable over recent years.